Tandem Diabetes Care (TNDM)
(Delayed Data from NSDQ)
$35.24 USD
-0.32 (-0.90%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $35.24 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
TNDM 35.24 -0.32(-0.90%)
Will TNDM be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for TNDM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TNDM
Earnings Preview: Tandem Diabetes Care, Inc. (TNDM) Q1 Earnings Expected to Decline
Tandem Diabetes (TNDM) Gains From Innovation Amid Macro Issues
TNDM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Inari Medical (NARI) Up 4% Since Last Earnings Report: Can It Continue?
Tandem Diabetes (TNDM) Gains From Innovation Amid Competition
Why Is Tandem Diabetes Care (TNDM) Up 27.4% Since Last Earnings Report?
Other News for TNDM
Leerink upgrades Tandem Diabetes to Outperform on attractive risk/reward setup
Leerink gets more bullish on Tandem Diabetes, upgrades shares
What's Driving Tandem Diabetes Care Inc's Surprising 31% Stock Rally?
Tandem Diabetes price target raised by $3 at Stifel, here's why
Cracking The Code: Understanding Analyst Reviews For Tandem Diabetes Care